Current and historical daily PE Ratio for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (
SHSE:600329
) from 2001 to May 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Tianjin Pharmaceutical Da Ren Tang Group stock (SHSE:600329) PE ratio as of May 16 2024 is 28.94.
More Details
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) PE Ratio (TTM) Chart
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) PE Ratio (TTM) Historical Data
View and export this data going back to 2001. Start your Free Trial
Total 1189
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Tianjin Pharmaceutical Da Ren Tang Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-16 | 28.9 | 2024-03-12 | 23.9 |
| 2024-05-15 | 29.3 | 2024-03-11 | 23.2 |
| 2024-05-14 | 29.6 | 2024-03-08 | 22.9 |
| 2024-05-13 | 28.6 | 2024-03-07 | 22.6 |
| 2024-05-10 | 28.1 | 2024-03-06 | 23.1 |
| 2024-05-09 | 28.2 | 2024-03-05 | 23.6 |
| 2024-05-08 | 27.8 | 2024-03-04 | 24.2 |
| 2024-05-07 | 28.2 | 2024-03-01 | 23.4 |
| 2024-05-06 | 28.0 | 2024-02-29 | 23.4 |
| 2024-05-03 | 27.8 | 2024-02-28 | 22.9 |
| 2024-05-02 | 27.8 | 2024-02-27 | 23.2 |
| 2024-04-30 | 27.8 | 2024-02-26 | 22.9 |
| 2024-04-29 | 26.8 | 2024-02-23 | 22.9 |
| 2024-04-26 | 27.3 | 2024-02-22 | 22.9 |
| 2024-04-25 | 26.7 | 2024-02-21 | 22.8 |
| 2024-04-24 | 26.6 | 2024-02-20 | 22.8 |
| 2024-04-23 | 26.3 | 2024-02-19 | 22.6 |
| 2024-04-22 | 26.5 | 2024-02-16 | 22.8 |
| 2024-04-19 | 26.3 | 2024-02-09 | 22.8 |
| 2024-04-18 | 26.3 | 2024-02-08 | 22.8 |
| 2024-04-17 | 26.9 | 2024-02-07 | 22.6 |
| 2024-04-16 | 26.1 | 2024-02-06 | 21.1 |
| 2024-04-15 | 26.3 | 2024-02-05 | 19.5 |
| 2024-04-12 | 25.1 | 2024-02-02 | 19.4 |
| 2024-04-11 | 24.7 | 2024-02-01 | 20.4 |
| 2024-04-10 | 24.4 | 2024-01-31 | 20.5 |
| 2024-04-09 | 24.5 | 2024-01-30 | 21.2 |
| 2024-04-08 | 23.9 | 2024-01-29 | 22.5 |
| 2024-04-05 | 24.3 | 2024-01-26 | 22.5 |
| 2024-04-03 | 24.3 | 2024-01-25 | 23.6 |
| 2024-04-02 | 23.4 | 2024-01-24 | 22.7 |
| 2024-04-01 | 23.8 | 2024-01-23 | 23.0 |
| 2024-03-29 | 22.1 | 2024-01-22 | 23.1 |
| 2024-03-28 | 22.3 | 2024-01-19 | 24.4 |
| 2024-03-27 | 21.8 | 2024-01-18 | 25.0 |
| 2024-03-26 | 22.0 | 2024-01-17 | 24.5 |
| 2024-03-25 | 21.9 | 2024-01-16 | 25.0 |
| 2024-03-22 | 21.9 | 2024-01-15 | 24.7 |
| 2024-03-21 | 22.5 | 2024-01-12 | 24.1 |
| 2024-03-20 | 22.6 | 2024-01-11 | 24.8 |
| 2024-03-19 | 23.0 | 2024-01-10 | 24.7 |
| 2024-03-18 | 23.5 | 2024-01-09 | 27.4 |
| 2024-03-15 | 23.3 | 2024-01-08 | 27.4 |
| 2024-03-14 | 23.4 | 2024-01-05 | 27.4 |
| 2024-03-13 | 23.7 | 2024-01-04 | 28.0 |
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
NAICS : 325412
ISIN : CNE000001808
Share Class Description:
SHSE:600329: Class ACompare
Compare
Traded in other countries / regions
600329.ChinaT14.Singapore2TZ.Germany IPO Date
2001-06-06Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers